|
|
 |
|
Inventory
Management Overview |
|
|
Pharmaceutical
companies are revising relationships with their distributors
in response to critical U.S. Wholesaler issues with counterfeits,
diversionary techniques, charge back/rebate documentation and
other distribution process issues. Manufacturers are concerned
with proper handling of their products, sufficient in-stock levels,
the avoidance of speculative buying, proper cold chain management,
charge back and returns system integrity, transparent and reliable
data flow, and compliance with industry regulations and guidelines
for pharmaceutical distribution system integrity.
In the short term, major pharmaceutical companies are evaluating
their current U.S. wholesaler agreements to meet the manufacturers' distribution
goals for its product line and to reduce legal risk.
Two fundamental U.S. distribution events have occurred in the last
decade (1995-2004) that created extraordinary Distribution buying
power concentration and leverage.
1. Major Wholesaler Industry Consolidation
(1995-2001).
2. Consolidated Wholesaler Industry
Asserting Power Base (2002-2005).
The big wholesalers have effectively changed the business model for
distribution, and in the process have caused Manufacturers to consider
the enforcement of new business terms with their distributors. Now
that new agreements are being adopted, Manufacturers want to assure
compliance with these terms and conditions and have begun auditing
their distributors to those terms.
SynTegra offers services to manufacturers who are revising their
distributor agreements and has a fully tested, standard process for
auditing distributors to assure distributor compliance.
|
|
 |
|
|
|
